|
|||||
|
|
Safety and Effectiveness of Ledipasvir and Sofosbuvir,With or Without Ribavirin,in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis |
|
| Authors: | Joseph K. Lim Ann Marie Liapakis Mitchell L. Shiffman Anna S. Lok Stefan Zeuzem Norah A. Terrault James S. Park Charles S. Landis Mohamed Hassan Joel Gallant Alexander Kuo Paul J. Pockros Monika Vainorius Lucy Akushevich Larry Michael Michael W. Fried David R. Nelson Ziv Ben-Ari |
| Affiliation: | 1. Yale University School of Medicine, New Haven, Connecticut;3. Liver Institute of Virginia, Richmond, Virginia;4. University of Michigan, Ann Arbor, Michigan;6. J. W. Goethe University Hospital, Frankfurt, Germany;5. University of California-San Francisco, San Francisco, California;7. University of Washington, Seattle, Washington;12. University of Minnesota, Minneapolis, Minnesota;8. Southwest CARE Center, Santa Fe, New Mexico;10. Virginia Mason Medical Center, Seattle, Washington;9. Scripps Clinic, La Jolla, California;71. University of Florida, Gainesville, Florida;123. Sheba Medical Center, Ramat Gan, Israel |
| Abstract: | |
| Keywords: | Real World Liver Disease Viral Hepatitis Therapy HCV-TARGET AE adverse event CI confidence interval DAA direct-acting antiviral agent EP evaluable population GT genotype HCC hepatocellular carcinoma HCV hepatitis C virus LDV ledipasvir MELD Model for End-Stage Liver Disease OLT orthotopic liver transplantation OR odds ratio PegIFN pegylated interferon PP per protocol RBV ribavirin SOF sofosbuvir SVR sustained virologic response TE treatment-experienced |
| 本文献已被 ScienceDirect 等数据库收录！ | |